For the Inventor, By the Inventor

Enter assignee name

Hayward, CA, United States of America

Metabolex, Inc.

USPTO Granted Patents = 41

% Expired Patents = 75.6

EPO Patents = 5

Trademarks = 1

Forward Citations = 236

Loading Chart...

Loading Chart...

50 inventors (with patents filed for the assignee):

Jeffrey D Johnson (13 out of 120 patents)

Xin Chen (13 out of 20 patents)

Jingyuan Ma (12 out of 19 patents)

4. Zuchun Zhao (11 out of 39 patents)

5. Jiangao Song (9 out of 24 patents)

6. Peng Cheng (8 out of 15 patents)

7. Imad Nashashibi (8 out of 16 patents)

8. Yan Zhu (8 out of 25 patents)

9. Christopher J Rabbat (6 out of 11 patents)

10. Yun-Ping Zhou (6 out of 9 patents)

11. Jian Luo (5 out of 32 patents)

12. John E Blume (5 out of 24 patents)

13. Aaron Robert Novack (5 out of 16 patents)

14. Dong Fang Shi (5 out of 6 patents)

15. John F Palma (5 out of 11 patents)

Core Competencies:

GPR120 Receptor Agonists

PPAR Modulators

Insulin Resistance

Type 2 Diabetes

Hyperlipidemia

Dyslipidemia

Crystalline Forms

Pharmaceutical Compositions

Heterocyclic Compounds

Apoptosis Signaling

Thiazole Derivatives

Phenylacetic Acids

41 patents: Sort by Forward Citations

1. 8598374 - GPR120 receptor agonists and uses thereof (2013-12-03),

2. 8541614 - Process for the preparation of (−)-(4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester (2013-09-24),

3. 8507719 - Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto (2013-08-13),

4. 8481597 - Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia (2013-07-09),

5. 8476308 - GPR120 receptor agonists and uses thereof (2013-07-02),

6. 8410127 - Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts (2013-04-02),

7. 8354448 - Use of (−)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of type 2 diabetes (2013-01-15),

8. 8329749 - Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia (2012-12-11),

9. 8309600 - GPR120 receptor agonists and uses thereof (2012-11-13),

10. 8299117 - GPR120 receptor agonists and uses thereof (2012-10-30),

11. 8288438 - Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer (2012-10-16),

12. 8288384 - Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders (2012-10-16),

13. 8227495 - 2,4-disubsituted thiazoles and pharmaceutical compositions thereof (2012-07-24),

14. 8203019 - Crystalline solid and amorphous forms of (−)- halofenate and methods related thereto (2012-06-19),

15. 8183381 - N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders (2012-05-22),

Metabolex, Inc., based in Hayward, California, specializes in the development of innovative therapeutics targeting metabolic diseases. The company focuses on GPR120 receptor agonists and PPAR modulators to address conditions such as insulin resistance, type 2 diabetes, and hyperlipidemia. Their research encompasses advanced mechanisms like apoptosis signaling kinase and beta-cell potassium channels, aiming to improve patient outcomes through novel treatment strategies in the metabolic health sector.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

41 Patents

#16 in Hayward, CA

#1,985 in California

#8,427 in US

#16,669 in the World

Hayward, CA, United States of America

Metabolex, Inc.

Forward Citations = 236

50 inventors:

Jeffrey D Johnson (13 out of 120 patents)

Xin Chen (13 out of 20 patents)

Jingyuan Ma (12 out of 19 patents)

4. Zuchun Zhao (11 out of 39 patents)

5. Jiangao Song (9 out of 24 patents)

Please report any incorrect information to [email protected]

Loading…